Loading
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Previous close
$8.82
+$0.02 · +0.23%
Regular session · ET · Market data may be delayed.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Day range
Current $8.82
52-week range
Current $8.82
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
7
Overpriced
Sentiment
64
Bullish
Risk
56
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Day range
Current $8.82
52-week range
Current $8.82
Third-party consensus; not a GoAI recommendation.
Average target
$12.40
40.59% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG95.36M4.75%1.56B USD0.75%$47.14-0.13%
State Street SPDR S&P Biotech ETFXBI48.53M0.42%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI34.72M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM31.3M0.04%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF12.28M0.01%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB9.87M0.09%10.72B USD0.44%$211.92-0.88%
iShares Russell 2000 Growth ETFIWO9.48M0.06%14.58B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO6.04M0.03%17.4B USD0.06%$119.62+0.25%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
